FindTrial
Sign In

A study on ear damage caused by anti-cancer drug (Cisplatin)- to find out the number of cases and the risk factors for occurrence of ear damage caused by the drug.

CROSS SECTIONAL STUDY OF PREVALENCE, RISK FACTORS AND FOLLOW-UP OF OTOTOXICITY INDUCED BY CISPLATIN BASED CHEMOTHERAPY

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/05/053252
Enrollment
100
Registered
2023-05-30
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C801- Malignant (primary) neoplasm, unspecified

Interventions

None listed

Sponsors

KASTURBA MEDICAL COLLEGE, MANIPAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Malignancy patients going to start Cisplatin treatment.

Exclusion criteria

Exclusion criteria: Head and neck malignancy patients with Radiotherapy treatment

Design outcomes

Primary

MeasureTime frame
To study development of Ototoxicity and quantify hearing loss in cancer patients receiving Cisplatin based chemotherapyTimepoint: pre-chemotherapy (baseline) after 2nd cycle (1 - 1/2 months) after 4th cycle—

Secondary

MeasureTime frame
Compare factors such as dosage, disease, sex and other non-confounding factors.Timepoint: pre-chemotherapy (baseline) after 2nd cycle (1 - 1/2 months) after 4th cycle—

Countries

India

Contacts

Public ContactDR POORVI SHARMA

KASTURBA MEDICAL COLLEGE

bala.ent@manipal.edu9845383714

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026